|
|
|
Neuropathy Clinical Trials, Diagnosis, and Treatment |
|
Thank you for your interest in clinical trials for
Neuropathy.
Please click "Search" to find Neuropathy clinical trials and medical research
studies or read below for information on Neuropathy diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the
locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 4 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-11030
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Manshasette, NY
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-19013
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Upland, PA
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-19107
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Philadelphia, PA
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-20892
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Bethesda, MD
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-33701
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: St. Petersburg, FL
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-34205
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Bradenton, FL
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-35801
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Huntsville, AL
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-39401
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Hattiesburg, MS
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-66160
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Kansas City, KS
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-72205
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Little Rock, AR
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-77030
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Houston, TX
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-85340
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Scottsdale, AZ
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-92697
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Irvine, CA
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa - NCT00782340-98034
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH) - Non-diabetic Neuropathy - Primary Autonomic Failure - Dopamine Beta Hydroxylase Deficiency Location: Kirkland, WA
- A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients - NCT00659269-87131
Conditions: Chemotherapy-Induced Neuropathy in Cancer Patients Location: Albuquerque, NM
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-07922
Conditions: Breast Cancer Location: Berkeley Heights, NJ
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-27607
Conditions: Breast Cancer Location: Raleigh, NC
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-32605
Conditions: Breast Cancer Location: Gainesville, FL
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-33428
Conditions: Breast Cancer Location: Boca Raton, FL
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-34471
Conditions: Breast Cancer Location: Ocala, FL
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-34952
Conditions: Breast Cancer Location: Port St. Lucie, FL
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-46219
Conditions: Breast Cancer Location: Indianapolis, IN
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-60611
Conditions: Breast Cancer Location: Chicago, IL
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-70072
Conditions: Breast Cancer Location: Marrero, LA
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-70115
Conditions: Breast Cancer Location: New Orleans, LA
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-75075
Conditions: Breast Cancer Location: Plano, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-75230
Conditions: Breast Cancer Location: Dallas, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-75231
Conditions: Breast Cancer Location: Dallas, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-75702
Conditions: Breast Cancer Location: Tyler, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-76033
Conditions: Breast Cancer Location: Houston, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-77024
Conditions: Breast Cancer Location: Houston, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-78405
Conditions: Breast Cancer Location: Corpus Christi, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-78410
Conditions: Breast Cancer Location: Corpus Christi, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-78759
Conditions: Breast Cancer Location: Austin, TX
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-84403
Conditions: Breast Cancer Location: Ogden, UT
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-86336
Conditions: Breast Cancer Location: Sedona, AZ
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-90250A
Conditions: Breast Cancer Location: Hawthorne, CA
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-90250B
Conditions: Breast Cancer Location: Hawthorne, CA
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-92868
Conditions: Breast Cancer Location: Orange, CA
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-97213
Conditions: Breast Cancer Location: Portland, OR
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-97225
Conditions: Breast Cancer Location: Portland, OR
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-97227
Conditions: Breast Cancer Location: Portland, OR
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer - NCT00879086-98684
Conditions: Breast Cancer Location: Vancouver, WA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-01915
Conditions: Optic Neuropathy, Ischemic Location: Beverly, MA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-02114
Conditions: Optic Neuropathy, Ischemic Location: Boston, MA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-02747
Conditions: Optic Neuropathy, Ischemic Location: North Dartmouth, MA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-03104
Conditions: Optic Neuropathy, Ischemic Location: Manchester, NH
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-03756
Conditions: Optic Neuropathy, Ischemic Location: Lebanon, NH
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-06488
Conditions: Optic Neuropathy, Ischemic Location: Southbury, CT
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-06510
Conditions: Optic Neuropathy, Ischemic Location: New Haven, CT
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-06708
Conditions: Optic Neuropathy, Ischemic Location: Waterbury, CT
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-07666
Conditions: Optic Neuropathy, Ischemic Location: Teaneck, NJ
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-08901
Conditions: Optic Neuropathy, Ischemic Location: New Brunswick, NJ
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-10021
Conditions: Optic Neuropathy, Ischemic Location: New York, NY
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-11788
Conditions: Optic Neuropathy, Ischemic Location: Woodbury, NY
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-11794
Conditions: Optic Neuropathy, Ischemic Location: Stony Brook, NY
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-12110
Conditions: Optic Neuropathy, Ischemic Location: Latham, NY
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-14642
Conditions: Optic Neuropathy, Ischemic Location: Rochester, NY
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-15212
Conditions: Optic Neuropathy, Ischemic Location: Pittsburgh, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-17602
Conditions: Optic Neuropathy, Ischemic Location: Lancaster, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-19102
Conditions: Optic Neuropathy, Ischemic Location: Philadelphia, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-19104
Conditions: Optic Neuropathy, Ischemic Location: Philadelphia, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-19107
Conditions: Optic Neuropathy, Ischemic Location: Philadelphia, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-19114
Conditions: Optic Neuropathy, Ischemic Location: Philadelphia, PA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-20007
Conditions: Optic Neuropathy, Ischemic Location: Washington, DC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-20037
Conditions: Optic Neuropathy, Ischemic Location: Washington, DC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-21204
Conditions: Optic Neuropathy, Ischemic Location: Baltimore, MD
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-21287
Conditions: Optic Neuropathy, Ischemic Location: Baltimore, MD
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-23226A
Conditions: Optic Neuropathy, Ischemic Location: Richmond, VA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-23226B
Conditions: Optic Neuropathy, Ischemic Location: Richmond, VA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-23298
Conditions: Optic Neuropathy, Ischemic Location: Richmond, VA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-23831
Conditions: Optic Neuropathy, Ischemic Location: Chester, VA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-23834
Conditions: Optic Neuropathy, Ischemic Location: Colonial Heights, VA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-27705
Conditions: Optic Neuropathy, Ischemic Location: Durham, NC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-28210
Conditions: Optic Neuropathy, Ischemic Location: Charlotte, NC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-29425
Conditions: Optic Neuropathy, Ischemic Location: Charleston, SC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-29615
Conditions: Optic Neuropathy, Ischemic Location: Greenville, SC
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-30322
Conditions: Optic Neuropathy, Ischemic Location: Atlanta, GA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-30909
Conditions: Optic Neuropathy, Ischemic Location: Augusta, GA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-33136
Conditions: Optic Neuropathy, Ischemic Location: Miami, FL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-33612
Conditions: Optic Neuropathy, Ischemic Location: Tampa, FL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-33901
Conditions: Optic Neuropathy, Ischemic Location: Fort Myers, FL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-34208
Conditions: Optic Neuropathy, Ischemic Location: Bradenton, FL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-35294
Conditions: Optic Neuropathy, Ischemic Location: Birmingham, AL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-36606
Conditions: Optic Neuropathy, Ischemic Location: Mobile, AL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-43215
Conditions: Optic Neuropathy, Ischemic Location: Columbus, OH
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-45242
Conditions: Optic Neuropathy, Ischemic Location: Cincinnati, OH
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-48105
Conditions: Optic Neuropathy, Ischemic Location: Ann Arbor, MI
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-48202
Conditions: Optic Neuropathy, Ischemic Location: Detroit, MI
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-52002
Conditions: Optic Neuropathy, Ischemic Location: Dubuque, IA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-55416
Conditions: Optic Neuropathy, Ischemic Location: Minneapolis, MN
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-55455
Conditions: Optic Neuropathy, Ischemic Location: Minneapolis, MN
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-60532
Conditions: Optic Neuropathy, Ischemic Location: Lisle, IL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-60637
Conditions: Optic Neuropathy, Ischemic Location: Chicago, IL
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-63104
Conditions: Optic Neuropathy, Ischemic Location: St. Louis, MO
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-64154
Conditions: Optic Neuropathy, Ischemic Location: Kansas City, MO
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-66208
Conditions: Optic Neuropathy, Ischemic Location: Prairie Village, KS
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-68198
Conditions: Optic Neuropathy, Ischemic Location: Omaha, NE
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-70807
Conditions: Optic Neuropathy, Ischemic Location: Baton Rouge, LA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-70810
Conditions: Optic Neuropathy, Ischemic Location: Baton Rouge, LA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-71270
Conditions: Optic Neuropathy, Ischemic Location: Ruston, LA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-72205
Conditions: Optic Neuropathy, Ischemic Location: Little Rock, AR
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-72212
Conditions: Optic Neuropathy, Ischemic Location: Little Rock, AR
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-77030
Conditions: Optic Neuropathy, Ischemic Location: Houston, TX
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-78705
Conditions: Optic Neuropathy, Ischemic Location: Austin, TX
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-80012
Conditions: Optic Neuropathy, Ischemic Location: Aurora, CO
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-80045
Conditions: Optic Neuropathy, Ischemic Location: Aurora, CO
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-84132
Conditions: Optic Neuropathy, Ischemic Location: Salt Lake City, UT
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-85704
Conditions: Optic Neuropathy, Ischemic Location: Tucson, AZ
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-90025
Conditions: Optic Neuropathy, Ischemic Location: Los Angeles, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-90033
Conditions: Optic Neuropathy, Ischemic Location: Los Angeles, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-90095
Conditions: Optic Neuropathy, Ischemic Location: Los Angeles, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-90813
Conditions: Optic Neuropathy, Ischemic Location: Long Beach, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-91105
Conditions: Optic Neuropathy, Ischemic Location: Pasadena, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-92056
Conditions: Optic Neuropathy, Ischemic Location: Oceanside, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-92354
Conditions: Optic Neuropathy, Ischemic Location: Loma Linda, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-94024
Conditions: Optic Neuropathy, Ischemic Location: Los Altos, CA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-97239
Conditions: Optic Neuropathy, Ischemic Location: Portland, OR
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-98104
Conditions: Optic Neuropathy, Ischemic Location: Seattle, WA
- A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION - NCT00759174-99501
Conditions: Optic Neuropathy, Ischemic Location: Anchorage, AK
- A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy - NCT00993018-
Conditions: Pain - Diabetic Neuropathy, Painful Location: Renton, WA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-10032
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: New York, NY
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-28139
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Rutherfordton, NC
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-29303A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Spartanburg, SC
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-29303B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Spartanburg, SC
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-29615
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Greenville, SC
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-29621
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Anderson, SC
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-31405
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Savannah, GA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-33428
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Boca Raton, FL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-33486
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Boca Raton, FL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-39216
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Jackson, MS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-39581
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Pascagoula, MS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-41101
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Ashland, KY
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43015
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Delaware, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43055
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Newark, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43081
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Westerville, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43130
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Lancaster, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43214
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Columbus, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43215A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Columbus, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43215B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Columbus, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43222
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Columbus, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43228
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Columbus, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43311
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Bellefontaine, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-43701
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Zanesville, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-44307
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Akron, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45005
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Franklin, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45177
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wilmington, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45331
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Greenville, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45373
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Troy, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45385
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Xenia, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45405
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dayton, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45406
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dayton, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45409
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dayton, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45415
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dayton, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45429A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dayton, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45429B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Kettering, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45504
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45505
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45601
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Chillicothe, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45750
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Marietta, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-45840
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Findlay, OH
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-46107
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Beech Grove, IN
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-47374
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Richmond, IN
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48060
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Port Huron, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48093
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Warren, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48106A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Ann Arbor, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48106B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Ann Arbor, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48123
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dearborn, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48154
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Livonia, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48236
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Grosse Pointe Woods, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48341
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Pontiac, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48503A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Flint, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48503B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Flint, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48601
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Saginaw, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-48912
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Lansing, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-49201
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Jackson, MI
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-52803
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Davenport, IA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-52804
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Davenport, IA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59101A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Billings, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59101B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Billings, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59101C
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Billings, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59101D
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Billings, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59107
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Billings, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59405A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Great Falls, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59405B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Great Falls, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59405C
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Great Falls, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59405D
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Great Falls, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59501
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Havre, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59601
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Helena, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59701
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Butte, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59715
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Bozeman, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59801
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Missoula, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59804
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Missoula, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59807A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Missoula, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59807B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Missoula, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59901A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Kalispell, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59901B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Kalispell, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-59901C
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Kalispell, MT
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-60153
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Maywood, IL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-62002
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Alton, IL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-62526
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Decatur, IL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-62781
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, IL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-62864
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Mt. Vernon, IL
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-63109
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Saint Louis, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-63141A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Saint Louis, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-63141B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Saint Louis, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-63703
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Cape Girardeau, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-65802
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-65804
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-65807
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Springfield, MO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-66044
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Lawrence, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-66606
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Topeka, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-66701
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Fort Scott, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-66720
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Chanute, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67003
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Anthony, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67042A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: El Dorado, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67042B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Salina, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67068
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Kingman, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67114
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Newton, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67124
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Pratt, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67152
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wellington, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67156
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Winfield, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67208A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wichita, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67208B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wichita, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67214A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wichita, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67214B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wichita, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67214C
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Wichita, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67301
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Independence, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67357
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Parsons, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67801
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Dodge City, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-67901
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Liberal, KS
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-71130
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Shreveport, LA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-71210
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Monroe, LA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-80045
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Aurora, CO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-80524
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Fort Collins, CO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-81401
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Montrose, CO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-81601
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Glenwood Springs, CO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-81632
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Edwards, CO
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-82609
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Casper, WY
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-82801
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Sheridan, WY
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-89102
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Las Vegas, NV
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-89106
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Las Vegas, NV
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-90089
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Los Angeles, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94040
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Mountain View, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94063
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Redwood City, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94080
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: South San Francisco, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94115
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: San Francisco, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94531
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Antioch, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94538A
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Fremont, CA
- Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy - NCT00775645-94538B
Conditions: Breast Cancer - Chemotherapeutic Agent Toxicity - Fatigue - Neurotoxicity Location: Fremont, CA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|